Large RCT Finds No Mortality Difference Between Two Major Anesthesia Types

For the millions of adults over 50 who undergo major elective surgery each year, the choice of anesthetic technique has long carried clinical debate and real anxiety. Anesthesiologists and patients alike have wondered whether propofol-based intravenous anesthesia offers meaningful protection over inhaled volatile agents — a question this large randomized trial directly addresses with hard outcome data.

The trial enrolled adults aged 50 and older undergoing major elective noncardiac surgery and randomized them to receive general anesthesia maintenance via either total intravenous anesthesia (TIVA), primarily propofol-based, or volatile inhalational agents such as sevoflurane or desflurane. The primary outcome focused on clinically significant endpoints including mortality and major complications at 30 days. Across the full cohort, no statistically significant difference emerged between the two techniques on the primary composite outcome, suggesting that at a population level, neither approach holds a decisive clinical advantage for survival or major morbidity in this surgical context.

This finding carries important nuance for the broader research landscape. Prior observational data had suggested propofol-based TIVA might reduce postoperative nausea, cancer recurrence risk, and inflammatory responses — hypotheses that drove significant clinical enthusiasm and some practice shifts. This trial, as a properly randomized design, provides a much stronger evidentiary counterweight to those observational signals. That said, it is worth noting the study population was defined by age and surgical type, meaning results may not generalize to cardiac surgery, pediatric populations, or oncologic procedures where the TIVA-cancer hypothesis remains particularly active. The trial also cannot rule out subgroup benefits that aggregate analysis obscures. From a longevity and healthspan perspective, the reassuring takeaway is that patients and clinicians may prioritize other individualized factors — cost, provider expertise, nausea history, or specific comorbidities — without fear of dramatically worsening survival outcomes through technique selection alone. This is confirmatory in spirit but meaningfully closes a long-standing evidentiary gap.